CN107814789B8 - Method for synthesizing daclatasvir starting material - Google Patents

Method for synthesizing daclatasvir starting material Download PDF

Info

Publication number
CN107814789B8
CN107814789B8 CN201711207599.6A CN201711207599A CN107814789B8 CN 107814789 B8 CN107814789 B8 CN 107814789B8 CN 201711207599 A CN201711207599 A CN 201711207599A CN 107814789 B8 CN107814789 B8 CN 107814789B8
Authority
CN
China
Prior art keywords
daclatasvir
starting material
formula
synthesizing
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711207599.6A
Other languages
Chinese (zh)
Other versions
CN107814789B (en
CN107814789A (en
Inventor
游新雨
陶鑫
韩加齐
史鹤峰
季翔
罗安贸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHANGZHOU YINSHENG PHARMACEUTICAL CO LTD
Original Assignee
CHANGZHOU YINSHENG PHARMACEUTICAL CO LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHANGZHOU YINSHENG PHARMACEUTICAL CO LTD filed Critical CHANGZHOU YINSHENG PHARMACEUTICAL CO LTD
Priority to CN202011462952.7A priority Critical patent/CN112480084B/en
Priority to CN202011464085.0A priority patent/CN112409336B/en
Priority to CN201711207599.6A priority patent/CN107814789B8/en
Publication of CN107814789A publication Critical patent/CN107814789A/en
Application granted granted Critical
Publication of CN107814789B publication Critical patent/CN107814789B/en
Publication of CN107814789B8 publication Critical patent/CN107814789B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention relates to a method for synthesizing daclatasvir starting material, which comprises the steps of reacting 2, 4' -dibromoacetophenone shown in a formula I, L-BOC-proline shown in a formula II, potassium carbonate and toluene to generate an intermediate product shown in a formula III, and reacting the intermediate product shown in the formula III with ammonium acetate to generate a compound shown in a formula IV. The synthesis method of the daclatasvir starting material has the advantages of simple reaction route and low cost of raw materials, and is suitable for industrial production.
CN201711207599.6A 2017-11-27 2017-11-27 Method for synthesizing daclatasvir starting material Active CN107814789B8 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202011462952.7A CN112480084B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material with simple reaction route
CN202011464085.0A CN112409336B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material suitable for industrial production
CN201711207599.6A CN107814789B8 (en) 2017-11-27 2017-11-27 Method for synthesizing daclatasvir starting material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711207599.6A CN107814789B8 (en) 2017-11-27 2017-11-27 Method for synthesizing daclatasvir starting material

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202011464085.0A Division CN112409336B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material suitable for industrial production
CN202011462952.7A Division CN112480084B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material with simple reaction route

Publications (3)

Publication Number Publication Date
CN107814789A CN107814789A (en) 2018-03-20
CN107814789B CN107814789B (en) 2020-12-15
CN107814789B8 true CN107814789B8 (en) 2021-01-01

Family

ID=61610455

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011462952.7A Active CN112480084B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material with simple reaction route
CN202011464085.0A Active CN112409336B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material suitable for industrial production
CN201711207599.6A Active CN107814789B8 (en) 2017-11-27 2017-11-27 Method for synthesizing daclatasvir starting material

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202011462952.7A Active CN112480084B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material with simple reaction route
CN202011464085.0A Active CN112409336B (en) 2017-11-27 2017-11-27 Synthetic method of daclatasvir starting material suitable for industrial production

Country Status (1)

Country Link
CN (3) CN112480084B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
CN103189371A (en) * 2010-11-04 2013-07-03 施万制药 Novel inhibitors of hepatitis C virus
WO2015017382A1 (en) * 2013-07-29 2015-02-05 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015124063A1 (en) * 2014-02-21 2015-08-27 常州寅盛药业有限公司 Hepatitis c virus inhibitors and uses thereof in preparation of drugs
CN106256825A (en) * 2016-07-04 2016-12-28 四川同晟生物医药有限公司 The synthetic method of his Wei of Dacca

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221737B2 (en) * 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102791687B (en) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 Novel inhibitors of hepatitis C virus replication
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
SI2850075T1 (en) * 2012-04-25 2017-06-30 Theravance Biopharma R&D Ip, Llc Piperazine-piperidine compounds as hepatitis c virus inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
CN103189371A (en) * 2010-11-04 2013-07-03 施万制药 Novel inhibitors of hepatitis C virus
WO2015017382A1 (en) * 2013-07-29 2015-02-05 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015124063A1 (en) * 2014-02-21 2015-08-27 常州寅盛药业有限公司 Hepatitis c virus inhibitors and uses thereof in preparation of drugs
CN106256825A (en) * 2016-07-04 2016-12-28 四川同晟生物医药有限公司 The synthetic method of his Wei of Dacca

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect;Min Gao等;《Nature》;20100506;第465卷;第96-100页 *

Also Published As

Publication number Publication date
CN112480084B (en) 2021-09-21
CN112409336B (en) 2021-09-14
CN107814789B (en) 2020-12-15
CN107814789A (en) 2018-03-20
CN112409336A (en) 2021-02-26
CN112480084A (en) 2021-03-12

Similar Documents

Publication Publication Date Title
WO2008089984A3 (en) Process for the preparation of ezetimibe and derivatives thereof
TW200726754A (en) Chemical process
UA104992C2 (en) Method for the synthesis of acrylonitrile from glycerol
WO2009095933A3 (en) Improved and novel process for the preparation of bosentan
UA102817C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR AGOMELATINE SYNTHESIS
MX2023004791A (en) Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl- benzyl)-4-(beta-d-glucopyranos-1 -yl)-benzene, l-proline and water.
UA102220C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR THE SYNTHESIS OF AGOMELATINE
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
NZ773997A (en) Method for producing 4-methoxy pyrrole derivative
MX2020006306A (en) Novel method for producing 5,5-disubstituted-4,5-dihydroisoxazole .
TN2009000401A1 (en) New methods
NZ586187A (en) Processes for the synthesis of sinomenine derivatives and their intermediate
WO2015120111A3 (en) Expedient synthesis of sitagliptin
WO2011130194A3 (en) Methods for producing viloxazine salts and novel polymorphs thereof
WO2011114210A3 (en) Processes for the preparation of linezolid
GB201204023D0 (en) Process for producing V-Coelenterazine compounds
WO2010148063A3 (en) Cyclohexene 1,4-carboxylates
WO2011119655A3 (en) Process for preparing divinlylarene dioxides
CN107814789B8 (en) Method for synthesizing daclatasvir starting material
WO2008094617A3 (en) Crystalline forms of deferasirox
UA102816C2 (en) Process for obtaining the crystalline form v of agomelatine
WO2012035303A8 (en) A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
MX2023000059A (en) Preparation method for phenylisoxazoline compound.
WO2012113999A8 (en) Process and intermediates for synthesizing agomelatine
EP4249491A3 (en) Process for preparing bicyclic enolether

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information

Inventor after: You Xinyu

Inventor after: Tao Xin

Inventor after: Han Jiaqi

Inventor after: Shi Hefeng

Inventor after: Ji Xiang

Inventor after: Luo Anmao

Inventor before: Tao Xin

Inventor before: Han Jiaqi

Inventor before: Shi Hefeng

Inventor before: Ji Xiang

Inventor before: Luo Anmao

CB03 Change of inventor or designer information
CI03 Correction of invention patent

Correction item: Inventor

Correct: You Xinyu|Tao Xin|Han Jiaqi|Shi Hefeng|Ji Xiang|Luo Anmao

False: Tao Xin|Han Jiaqi|Shi Hefeng|Ji Xiang|Luo Anmao

Number: 51-01

Page: The title page

Volume: 36

Correction item: Inventor

False: Tao Xin|Han Jiaqi|Shi Hefeng|Ji Xiang|Luo Anmao

Number: 51-01

Volume: 36

CI03 Correction of invention patent